Transfuse Hdose Imun Glob in Central Vein, Perc, New Tech 7

This code describes the administration of a large quantity of intravenous immune globulin (IVIG) directly into a central vein. This procedure is performed using a percutaneous approach, meaning the central vein is accessed through the skin without an open incision. The "New Technology Group 7" designation indicates that this specific IVIG product is considered a novel or advanced therapeutic agent.

This code is appropriate for inpatient encounters where high-dose IVIG is administered via a central line for conditions such as severe autoimmune disorders, certain neurological conditions, or primary immunodeficiencies. It is used when the specific IVIG product falls under the New Technology Group 7 classification. This code should be selected when the administration is the primary therapeutic intervention and not merely a supportive measure.

• Verify that the documentation explicitly states "high-dose" IVIG and confirms central venous access via a percutaneous approach.
• Ensure the specific IVIG product administered is identified as belonging to "New Technology Group 7."
• Do not use this code for standard or low-dose IVIG infusions, or for IVIG administered via peripheral veins.